The grant will help the company in the intended dosing conversion study of CD-LD ER to IPX066 in pateints with advanced PD pateints.
The company is also set to conduct ASCEND-PD comparative study of IPX066 and carbidopa-levodopa and entacapone.
Michael J Fox Foundation Research Programs director Brian Fiske said by collaborating with Impax Pharmaceuticals to develop additional clinical data about IPX066, they hope to gather important information for physicians treating PD and their patients.